Comparison of health-care utilization and expenditures for minimally invasive vs. open colectomy for benign disease

Sarah E. Diaz1 · Yongjin F. Lee2 · Amir L. Bastawrous2 · I.-Fan Shih3 · Shih-Hao Lee3 · Yanli Li3 · Robert K. Cleary1

Received: 20 November 2021 / Accepted: 7 February 2022 / Published online: 22 February 2022 © The Author(s) 2022

Abstract

Background  Adoption of minimally invasive approaches continues to increase, and there is a need to reassess outcomes and cost. We aimed to compare open versus minimally invasive colectomy short- and long-term health-care utilization and payer/patient expenditures for benign disease.

Methods  This is a retrospective analysis of IBM® MarketScan® Database patients who underwent left or right colectomy for benign disease between 2013 and 2018. Outcomes included total health-care expenditures, resource utilization, and direct workdays lost up to 365 days following colectomy. The open surgical approach (OS) was compared to minimally invasive colectomy (MIS) with subgroup analysis of laparoscopic (LS) and robotic (RS) approaches using inverse probability of treatment weighting.

Results  Of 10,439 patients, 2531 (24.3%) had open, 6826 (65.4%) had laparoscopic, and 1082 (10.3%) had robotic colectomy. MIS patients had shorter length of stay (LOS; mean difference, −1.71, p < 0.001) and lower average total expenditures (mean difference, −$2378, p < 0.001) compared with open patients during the index hospitalization. At 1 year, MIS patients had lower readmission rates, and fewer mean emergency and outpatient department visits than open patients, translating into additional savings of $5759 and 2.22 fewer days missed from work for health-care visits over the 365-day post-discharge period. Within MIS, RS patients had shorter LOS (mean difference, −0.60, p < 0.001) and lower conversion-to-open rates (odds ratio, 0.31, p < 0.001) during the index hospitalization, and lower hospital outpatient visits (mean difference, −0.31, p = 0.001) at 365 days than LS.

Conclusion  MIS colectomy is associated with lower mean health-care expenditures and less resource utilization compared to the open approach for benign disease at index operation and 365-days post-discharge. Health-care expenditures for LS and RS are similar but shorter mean LOS and lower conversion-to-open surgery rates were observed at index operation for the RS approach.

Keywords  Colon resection · Cost · Health-care utilization · Minimally invasive · Robotic-assisted surgery · Laparoscopic surgery

The development and introduction of minimally invasive surgery (MIS) tools and approaches have fundamentally changed colorectal surgery. MIS approaches to colorectal surgery offer several outcomes advantages over traditional open surgery (OS) that include earlier return of bowel function, less postoperative pain and opioid use, shorter hospital length of stay (LOS), and fewer surgical site infections [1–5]. The adoption of the MIS approach to colorectal surgery increased from 40 to 60% in 2011 to 75% in 2018 [6]. Early adoption of MIS was initially associated with higher costs due to instrumentation expenses and longer operating times [2]. Changes in reimbursement and bundled payments mandated consideration of short- and long-term costs generated by an index hospital episode [7].

With increasing adoption, it is important to reassess health-care utilization outcomes and cost to determine if the value of MIS has become more favorable with experience.
Long-term follow-up potentially reveals robotic surgery (RS) advantages of enhanced vision and articulated instruments that may cause less surgical trauma. This may be associated with decreased health-care expenditures and utilization due to fewer index surgery complications [8]. Previous studies of patients with colorectal cancer have demonstrated the value of MIS, but none have focused on benign disease or assessed value beyond 90 days after the initial hospitalization [8]. The aim of this study is to compare open and minimally invasive colectomy short- and long-term utilization outcomes and payer/patient expenditures for patients with benign disease at the index operation and up to 1 year after surgery with subgroup analysis of laparoscopic (LS) and robotic (RS) approaches.

Materials and methods

Data source

This is a retrospective claims data analysis using the IBM® MarketScan® Commercial Claims and Encounter Database (MarketScan®), an aggregated database that contains all paid claims and encounter data generated by approximately 50 million commercially insured individuals in the United States. The database includes inpatient, outpatient, and prescription drug service use, representing the medical experience of insured employees and their dependents [9]. As this was an observational study of de-identified patients in the MarketScan® database, Institutional Review Board approval and consent were exempt (in accordance with the Health Insurance Portability and Accountability Act Privacy Rule).

Study population

All adults aged 18–64 years in the database with an inpatient colectomy without a colon or rectal cancer diagnosis between January 2013 and December 2018 were identified. We used International Classification of Diseases and Related Health Problems, Ninth and Tenth Revisions, Clinical Modification and Procedure Classification System (ICD-9-CM/ICD-10-CM/ICD-9-PCS/ICD-10-PCS) to define the eligible colectomy cases and differentiate surgical approaches (Supplementary Table 1). To be eligible for data analysis, patients were required to be continuously enrolled with medical and prescription drug coverage from 180 days prior to and 365 days after inpatient colectomy. Exclusion criteria included: (1) emergent cases; (2) inpatient cases that were not coded with diagnosis-related group (DRG) codes 329, 330 or 331; (3) demographic information missing; (4) discharges with extreme total payment in index hospitalization (<1st or >99th); (5) patients with capitated payment insurance plans (health maintenance organization and capitated point-of-service) because these plans often submit claims with $0 pay value. Emergent cases were defined as patients who had an emergency room service claim found on the day of admission.

Outcomes

Study outcomes included mean total health-care expenditures, mean health-care resource utilization and mean direct workdays lost to health-care utilization. These outcomes were assessed during the index surgery and for 365 days post-discharge. The health-care expenditures included both facility and professional payments. Total expenditures were inflation adjusted to 2018 US dollars utilizing the general Consumer Price Index. Health-care utilization included inpatient readmission, emergency department visits, hospital outpatient, and office visits 1-year after the index procedure based on place of service. For direct work loss days due to health-care visits, we converted the LOS to days of utilization for inpatient claims, and assumed a half-day of utilization for an office visit claim, and a full day of utilization for claims related to emergency department, urgent care facility, or other hospital outpatient visit [10, 11].

Patient factors

Patient-level baseline sociodemographic and clinical characteristics included age, gender, region, insurance plan, metropolitan/non-metropolitan area, the indication for surgery (benign neoplasm, diverticular disease, inflammatory bowel disease), resection type (Left: left hemicolectomy and sigmoidectomy; Right: right hemicolectomy and coeectomy), and year of surgery. Insurance plans were classified into comprehensive insurance, preferred provider organization (PPO), non-capitated point-of-service (POS), and other insurance plans. DRG codes were listed in Table 1 but not included in statistical model. We measured comorbidity using the Charlson Comorbidity Index (CCI) presented at the index hospitalization and in the 180-day preoperative period.

Statistical analysis

All descriptive and statistical testing analyses were conducted comparing the open surgical approach to minimally invasive surgical approaches, and between LS and RS. Patient characteristics at baseline were summarized as frequencies with proportions for categorical variables and means with standard deviation for continuous variables. Inverse probability of treatment weighting (IPTW) was conducted to minimize the effect of potential confounding factors without reducing the sample size [12]. We applied stabilized propensity score weights to estimate average

Springer
treatment effect using a logistic regression model with all the baseline patient factors mentioned above. The covariates were selected based on prior knowledge and literature [10, 11, 13]. After IPTW, covariates were considered balanced if the absolute value of the standardized mean difference (SMD) was less than 0.10. Generalized linear model and logistic regression, weighted by the IPTWs and adjusting for the total health-care expenditures in the 180-day preoperative period (i.e., baseline expenditures) were used to estimate the health-care expenditures and utilization. Expenditures, hospital outpatient and office utilization and estimated days off from work were estimated using gamma distribution.

Table 1 Baseline demographic characteristics before IPTW adjustment

|                   | Open (N=2531) | MIS (N=7908) | SMD | LAP (N=6826) | RAS (N=1082) | SMD |
|-------------------|---------------|--------------|-----|--------------|--------------|-----|
| **Age**           |               |              |     |              |              |     |
| 18–44             | 507 (20.0)    | 1563 (19.8)  | 0.069| 1379 (20.2)  | 184 (17.0)   | 0.086|
| 45–54             | 826 (32.6)    | 2829 (35.8)  |     | 2439 (35.7)  | 390 (36.0)   |     |
| 55–64             | 1198 (47.3)   | 3516 (44.5)  |     | 3008 (44.1)  | 508 (47.0)   |     |
| **Sex**           |               |              |     |              |              |     |
| Male              | 1391 (55.0)   | 4093 (51.8)  | 0.064| 3559 (52.1)  | 534 (49.4)   | 0.056|
| Female            |               |              |     |              |              |     |
| **Region**        |               |              |     |              |              |     |
| North Central     | 641 (25.3)    | 1839 (23.3)  | 0.110| 1560 (22.9)  | 279 (25.8)   | 0.077|
| Northeast         | 347 (13.7)    | 1287 (16.3)  |     | 1127 (16.5)  | 160 (14.8)   |     |
| South             | 1284 (50.7)   | 3795 (48.0)  |     | 3289 (48.2)  | 506 (46.8)   |     |
| West              | 259 (10.2)    | 987 (12.5)   |     | 850 (12.5)   | 137 (12.7)   |     |
| **Insurance plan**|               |              |     |              |              |     |
| PPO               | 1680 (66.4)   | 5303 (67.1)  | 0.078| 4593 (67.3)  | 710 (65.6)   | 0.063|
| Comprehensive     | 151 (6.0)     | 354 (4.5)    |     | 294 (4.3)    | 60 (5.5)     |     |
| Non-capitated POS | 214 (8.5)    | 614 (7.8)    |     | 533 (7.8)    | 81 (7.5)     |     |
| Others            | 486 (19.2)    | 1637 (20.7)  |     | 1406 (20.6)  | 231 (21.3)   |     |
| **Charlson comorbidity** |       |               |     |              |              | 0.165|
| 0                 | 1387 (54.8)   | 4836 (61.2)  |     | 4192 (61.4)  | 644 (59.5)   | 0.053|
| 1                 | 556 (22.0)    | 1738 (22.0)  |     | 1501 (22.0)  | 237 (21.9)   |     |
| ≥ 2               | 588 (23.2)    | 1334 (16.9)  |     | 1133 (16.6)  | 201 (18.6)   |     |
| **Metropolitan**  |               |              |     |              |              | 0.195|
| Yes               | 519 (20.5)    | 1047 (13.2)  | 0.195| 905 (13.3)   | 142 (13.1)   | 0.004|
| No                |               |              |     |              |              |     |
| **DRG**           |               |              |     |              |              | 0.433|
| 329               | 516 (20.4)    | 801 (10.1)   |     | 702 (10.3)   | 99 (9.1)     | 0.095|
| 330               | 1314 (51.9)   | 3432 (43.4)  |     | 2996 (43.9)  | 436 (40.3)   |     |
| 331               | 701 (27.7)    | 3675 (46.5)  |     | 3128 (45.8)  | 547 (50.6)   |     |
| **Inflammatory bowel disease** |     |               |     |              |              | 0.197|
| Yes               | 451 (17.8)    | 865 (10.9)   | 0.197| 809 (11.9)   | 56 (5.2)     | 0.241|
| No                |               |              |     |              |              |     |
| **Benign colon neoplasm** |       |               |     |              |              | 0.182|
| Yes               | 552 (21.8)    | 2352 (29.7)  | 0.182| 2023 (29.6)  | 329 (30.4)   | 0.017|
| No                |               |              |     |              |              |     |
| **Diverticular disease** |       |               |     |              |              | 0.116|
| Yes               | 1463 (57.8)   | 5017 (63.4)  | 0.116| 4286 (62.8)  | 731 (67.6)   | 0.100|
| No                |               |              |     |              |              |     |
| **Year**          |               |              |     |              |              | 0.090|
| 2013              | 504 (19.9)    | 1529 (19.3)  |     | 1419 (20.8)  | 110 (10.2)   | 0.488|
| 2014              | 624 (24.7)    | 1875 (23.7)  |     | 1703 (24.9)  | 172 (15.9)   |     |
| 2015              | 569 (22.5)    | 1735 (21.9)  |     | 1515 (22.2)  | 220 (20.3)   |     |
| 2016              | 472 (18.6)    | 1381 (17.5)  |     | 1108 (16.2)  | 273 (25.2)   |     |
| 2017              | 362 (14.3)    | 1388 (17.6)  |     | 1081 (15.8)  | 307 (28.4)   |     |
| **Baseline total expenditures** |       |               |     |              |              |     |
| Mean ± SD         | $24297 ± $33552 | $17805 ± $23445 |     | $17988 ± $23866 | 16652 ± 20567 | 0.060|
| Median (Q1, Q3)   | $13579 ($5941, $28625) | $10678 ($5175, $21479) |     | $10758 ($5227, $21736) | $10266 ($4712, $19728) |     |

IPTW inverse probability of treatment weighting, SMD standard mean difference, MIS minimally invasive surgery, LS laparoscopic surgery, RS robotic surgery, POS Point-of-Service, PPO preferred provider organization, DRG Diagnosis-Related Group, DRG 329/330/331 major small and large bowel procedures
emergent department and inpatient services were modeled using zero-inflated Poisson in the generalized linear models. All analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC) and a 2-tailed \( p < 0.05 \) was considered statistically significant.

**Results**

After excluding emergent cases (\( n = 4958 \)), cases without DRG 329/330/331 codes (\( n = 698 \)), index payments < 1st or > 99th (\( n = 248 \)), cases with missing demographic information (\( n = 198 \)), and cases with capitated plans (\( n = 1467 \)), there were 10,439 eligible patients in the dataset, including 2531 (24.3%) OS, 6826 (65.4%) LS, and 1082 (10.3%) RS (Fig. 1). Table 1 shows baseline sociodemographic characteristics before IPTW. There were several differences in SMD before IPTW that included Region (SMD = 0.110) and DRG codes (SMD = 0.433). The OS group had significantly more patients with two or more comorbidities (23.2% vs 16.9%, SMD = 0.165), more patients located in metropolitan area (20.5% vs 13.2%, SMD = 0.195), more with inflammatory bowel disease (17.8% vs 10.9%, SMD = 0.197), and higher total baseline health-care expenditures (mean 24,297 vs $17,805, SMD = 0.224). The OS group had significantly fewer patients with benign neoplasm (21.8% vs 29.7%, SMD = 0.182) and diverticular disease (57.8% vs 63.4%, SMD = 0.116). The only significant difference between LS and RS groups prior to IPTW was the number of patients with diverticular disease (LS 62.8% vs RS 67.6%, SMD = 0.100). After IPTW, there were no significant sociodemographic differences between OS and MIS or between LS and RS groups (Supplementary Table 2).

Figure 2 shows IPTW-adjusted mean total expenditures between groups starting with the index surgery hospital stay, and up to 365 days post-discharge. Mean total expenditures were significantly higher for OS colectomy than for MIS colectomy at all time periods analyzed—index surgery episode ($35,169 vs $32,791, p < 0.001), from index to 30-day post-discharge ($39,123 vs $35,924, p < 0.001), 90-day post-discharge ($44,503 vs $40,128, p < 0.001), 180-day post-discharge ($51,602 vs $45,574, p < 0.001), 270-day post-discharge ($57,565 vs $50,442, p < 0.001), and 365-day post-discharge ($63,324 vs $55,200, p < 0.001). Subgroup analysis of LS vs RS revealed no significant differences in mean payer expenses for all time periods analyzed.

For IPTW-adjusted resource utilization, MIS showed several favorable outcomes when compared to the OS approach (Table 2). At the index surgery, LOS (mean 5.91 vs 4.20 days, \( p < 0.001 \)) and mean hospital payments ($30,176 vs $27,746, \( p < 0.001 \)) were significantly more for OS colectomy than for MIS. At 365 days after discharge, MIS patients were less likely to be readmitted (OR 0.53, \( p < 0.001 \)), visit the emergency department (OR 0.88, \( p = 0.008 \)) and visit the hospital outpatient department (OR 0.74, \( p < 0.001 \)) than OS patients. MIS patients also had lower mean inpatient LOS (mean difference, \(-0.99\) days, \( p < 0.001 \)), lower number of emergency department visits (mean difference, \(-0.08, p < 0.001 \)), and lower number of hospital outpatient visits (mean difference, \(-1.10, p < 0.001 \)). The reduction...
in health-care use among MIS patients translated into additional savings of $5759 and 2.22 days (both \( p < 0.001 \)) fewer days missed from work due to health-care visits over the 1-year post-discharge period.

Subgroup analysis of LS vs RS shows that index LOS (Table 3; mean 4.22 vs 3.63 days, \( p < 0.001 \)), conversion-to-open (8.0% vs 2.6%, \( p < 0.001 \)), and mean payments to physicians ($2872 vs $2653, \( p = 0.011 \)) were significantly more for LS than for RS. In addition, the average number of outpatient hospital visits at 1 year was significantly higher for the LS approach (mean difference, −0.31, \( p = 0.001 \)). There were no significant differences between LS and RS for all other outcomes and payments.

The impact of MIS conversion-to-open is shown in Table 4. At the index hospitalization, LOS (mean 5.44 vs 4.04 days, \( p < 0.001 \)) and hospital payments (mean $30,012 vs $27,263, \( p < 0.001 \)) were significantly more for MIS cases requiring conversion. At 1 year, converted cases had significantly more readmissions (23.2% vs 16.0%, \( p < 0.001 \)), inpatient hospital days (mean difference, −1.13 days, \( p < 0.001 \)), outpatient hospital visits (79.4% vs 73.2%, \( p = 0.002 \)) and average number of outpatient hospital visits (mean difference, −0.41, \( p < 0.002 \)). This translated into additional savings of $4816 and 1.46 fewer days missed from work for health-care visits over the 1-year post-discharge period.

Diverticular disease was the most common benign disease diagnosis, comprising 48.2% of the OS group and 55.4% of the MIS group (Supplementary Table 3 and Supplementary Figure S1). Most of the health-care utilization and expenditure outcomes for this subgroup were similar to the overall study results. Exceptions were that there was a significant
difference in index surgery physician payments (mean OS $2613 vs MIS $2887, \( p = 0.015 \)) and no significant difference in ER visits (OS 33.9% vs 33.6%, \( p = 0.848 \)) for patients with diverticular disease.

### Discussion

Previous studies have been limited by grouping together benign and malignant diagnoses, colon and rectal disease, or by limiting the analysis to malignant disease.
This large, national claims data analysis focuses on colectomy for benign disease and shows that MIS colectomy for benign disease is associated with lower mean health-care utilization and payer/patient expenses than open colectomy in both short- and long-term post-operative periods. Specifically, MIS is associated with shorter mean hospital LOS at the index hospitalization as well as lower readmission rates, mean number of ED and hospital outpatient department visits, and mean number of days missed from work during the first year after surgery. In addition, RS patients had shorter mean index hospital LOS, lower conversion-to-open surgery rates and less mean hospital outpatient visits after surgery when compared to the LS group. These findings likely reflect long-term MIS colectomy benefits that include faster recovery with fewer complications and less pain [1–5].

Previous studies have shown mixed results for the cost advantage of MIS and for what category advantages are most apparent [7, 8, 18, 19]. A large, regional risk-adjusted database study composed of Blue Cross Blue Shield of Michigan and Medicare price-standardized payments showed that costs associated with MIS colorectal surgery were significantly less than OS, even after accounting for the cost of conversion. The cost advantage for MIS was most evident in the index hospitalization and post-discharge care up to 90 days [7]. A population-based study of Medicare beneficiaries showed that the LS cost savings when compared to open colectomy were due to lower expenditures for complications, readmissions, and post-acute care [18]. Another New York State Cancer Registry analysis showed that there was no 90-day cost benefit for MIS over OS but that 90-day utilization, represented by hospital days, was decreased for both LS and RS approaches when compared to OS [8]. In contrast, our study showed significantly decreased expenditures associated with the MIS approach for all index hospitalization categories except physician payments and for post-discharge expenditures at all time periods up to one year after surgery. For health-care utilization, our study is consistent with a previous study showing decreased LOS and readmissions [8]. Our study also showed decreased mean number of ED and outpatient department visits for MIS compared to OS.

The cost of laparoscopic instrumentation, operative times, and concerns about the possible negative impact on outcomes limited widespread implementation of LS in colorectal surgery following the first report in 1991 [20]. For those mastering the learning curve and with LS experience, cost and outcomes studies ultimately demonstrated the benefit of this approach [7, 21]. Similarly, institutional costs of RS precluded wider implementation in some hospitals [7, 14], and the value of RS, when considering outcomes and cost, is currently debated in the literature [22, 23]. Like laparoscopic colorectal surgery, the cost of RS has decreased with time and experience, likely due to reductions in operative time, LOS, conversion-to-open, standardized surgical protocols, and surgeon volume defined as ≥ 30 cases per year [8, 24–26]. Previous studies have shown mixed results comparing LS and RS cost-effectiveness [2, 8, 16, 24, 27].

### Table 4 IPTW-adjusted differences in health care utilization and expenditures between MIS-complete and converted colectomies

|                      | MIS-Complete | Converted | Adjusted differences (MIS—Open) | p Value |
|----------------------|--------------|-----------|---------------------------------|---------|
|                      | Mean | %       | Mean | %       | Mean (95% CI) | OR (95% CI) |        |
| **Index surgery**    |      |         |      |         |                |            |        |
| LOS, days            | 4.04 | NA      | 5.44 | NA      | 1.39 (1.16, 1.63) | NA         | < 0.001 |
| Hospital payment, dollars | 27263 | NA    | 30012 | NA    | 2749 (1508, 3990) | NA         | < 0.001 |
| Physician payment, dollars | 2850 | NA    | 2778 | NA    | − 71 (− 301, 158) | NA         | 0.542   |
| Total payment, dollars | 32286 | NA    | 35028 | NA    | 2742 (1445, 4039) | NA         | < 0.001 |
| **1-year post surgery** |      |         |      |         |                |            |        |
| Total payment, dollars | 20332 | NA    | 25148 | NA    | 4816 (1938, 7693) | NA         | 0.001   |
| Readmission, %       | NA   | 16.0    | NA   | 23.2    | 1.13 (− 0.77, − 1.49) | NA         | < 0.001 |
| Inpatient LOS        | NA   | 51.3    | NA   | 31.4    | 1.00 (0.83, 1.21) | 0.974     |
| ER visit, %          | NA   | 0.57    | NA   | 0.58    | 1.00 (0.07, − 0.11) | NA         | 0.696   |
| Number of ER visits  | NA   | 73.2    | NA   | 79.4    | 1.41 (1.14, 1.75) | 0.002     |
| Hospital Outpatient visit, % | 3.80 | NA    | 4.21 | NA    | − 0.41 (− 0.16, − 0.67) | NA         | 0.002   |
| Number of outpatient visits | 11.26 | NA  | 10.88 | NA  | 0.39 (0.76, 0.01) | 0.045     |
| Number of office visits | 11.32 | NA  | 12.78 | NA  | 1.46 (0.46, 2.46) | NA         | 0.004   |

IPTW inverse probability of treatment weighting, MIS minimally invasive surgery, CI confidence interval, OR odds ratio, LOS length of stay, ER emergent room.
were significantly higher [2]. In contrast to our study, this database analysis relied on ICD-9 procedure codes and hospital charges, included an earlier time period than ours (2014 vs 2018), and may have included more patients in the robotic learning curve with longer operative times and more instrument needs.

Using an incremental cost-effectiveness ratio, estimated using overall costs and quality-adjusted life years, another recent comparison of LS and RS approaches for right colon cancer showed that there was no significant difference in costs between groups and that there was a 78.78–95.04% probability that the RS group was more cost effective compared to the LS group [27]. Our study showed no difference in mean expenditures between RS and LS approaches for all categories except physician payments (LS > RS, p = 0.01) at index surgery. In a subgroup analysis, we observed higher mean expenditures and utilization for converted than for non-converted MIS cases at index surgery and 1-year after surgery.

This study is retrospective with inherent limitations. These include associated biases (surgeon being the most glaring). The database also depends on dependable data entry, and ICD-9 and ICD-10 coding accuracy for surgical procedures. Patients were assigned the robotic approach if robotic and laparoscopic or open codes were identified in the same index surgery claim. The database lacks granular detail for surgical procedures and may potentially have absent data. There is the possibility of unidentified confounders due to unmeasured characteristics. The IBM® MarketScan® database does not account for surgeon selection bias choosing the operative approach, variations in surgeon volume, and enhanced recovery care elements that may impact outcomes and expenditures. This is a study of patients with colectomies and benign disease. The results may not be generalizable to those uninsured or having rectal resections. We are currently evaluating malignant disease in a separate analysis. The strengths of this study are the ability to evaluate real-world claims data rather than direct costs or charges associated with in-hospital care or the operative intervention, and using population-based data that represents surgeons and hospitals of varying degrees of expertise. Furthermore, the ability to evaluate the impact on outpatient expenditures and resource utilization up to one year after surgery are particular advantages to this study. This study adds to the cost analysis of colorectal surgery from a unique perspective. These data suggest that the continued increase in MIS adoption may translate into continued cost savings. Future cost analyses will likely include short-term considerations such as the cost of conversion and long-term considerations such as the ability to perform intracorporeal anastomoses that allow off-midline specimen extraction sites, thereby decreasing hernia rates with the associated morbidity and cost [7, 28, 29].

Conclusion

Minimally invasive colectomy is associated with lower mean health-care expenditures and less mean health-care resource utilization compared to the open approach for benign disease at the time of index surgery and at 365-days post-discharge. Health-care expenditures for laparoscopic and robotic colectomy are not significantly different, but shorter mean LOS and lower conversion-to-open surgery rates were observed at index operation for the RS approach. Future studies should consider other operative approach procedural differences that may impact health-care expenditures and resource utilization.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00464-022-09097-x.

Funding Access to the MarketScan database was provided by Intuitive Surgical.

Declarations

Disclosures Amir L Bastawrous has received honoraria from Intuitive Surgical, Inc. for educational speaking. He serves on the advisory board of Medtronic. He has equity interest in Twistle, Inc. I-Fan Shih, Shih-Hao Lee and Yanli Li are full-time employees of Intuitive Surgical, Inc. Robert K Cleary has received honoraria from Intuitive Surgical, Inc. for educational speaking. Sarah E Diaz and Yongjin F Lee have no conflict of interest or financial ties to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Batool F, Collins SD, Albright J, Ferraro J, Wu J, Krapohl GL, Campbell DA, Cleary RK (2018) A regional and national database comparison of colorectal outcomes. JSLS. https://doi.org/10.4293/JSLS.2018.00031
2. Alharthi S, Reilly M, Arishi A, Ahmed AM, Chulkov M, Qu W, Ortiz J, Nazazl M, Pannell S (2020) Robotic versus laparoscopic sigmoid colectomy: analysis of healthcare cost and utilization project database. Am Surg 86(3):256–260
3. Bastawrous AL, Shih I-F, Li Y, Cleary RK (2020) Minimally invasive sigmoidectomy for diverticular disease decreases inpatient
opioid use: results of a propensity score-matched study. Am J Surg 220(2):421–427
4. Mlamb0 B, Shih I-F, Li Y, Wren SM (2021) The impact of operative approach on postoperative outcomes and healthcare utilization after colectomy. Surgery. https://doi.org/10.1016/j.surg.2021.07.011
5. Bastawrous AL, Brockhaus KK, Chang MI, Milky G, Shih I-F, Li Y, Cleary RK (2021) A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use. Surg Endosc. https://doi.org/10.1007/s00464-021-08338-9
6. Unruh KR, Bastawrous AL, Bernier GV, Flum DR, Kumar AS, Moonka R, Thirby RC, Simianu VV (2019) Evaluating the regional uptake of robotic colorectal surgery: a report from the surgical care outcomes assessment program collaborative. J Am Coll Surg 229(4):e92
7. Cleary RK, Mullard AJ, Ferraro J, Regenbogen SE (2018) The cost of conversion in robotic and laparoscopic colorectal surgery. Surg Endosc 32(3):1515–1524
8. Justiniano CF, Becerra AZ, Xu Z, Aquina CT, Boodry CI, Schymura MJ, Boscoe FP, Noyes K, Temple LK, Fleming FJ (2020) A population-based study of 90-day hospital cost and utilization associated with robotic surgery in colon and rectal cancer. J Surg Res 245:136–144
9. IBM Watson Health (2018) MarketScan Commercial Claims and Encounter Database and Medicare Supplemental and Coordination of Benefits Research Databases User Guide (2018 Edition). IBM Corporation
10. Watson TJ, Qiu J (2016) The impact of thoracoscopic surgery on payment and health care utilization after lung resection. Ann Thorac Surg 101(4):1271–1280
11. Mikami D, Melvin WS, Murayama MJ, Murayama KM (2017) Impact of minimally invasive surgery on healthcare utilization, cost, and workplace absenteeism in patients with Incisional//Ventral Hernia (IVH). Surg Endosc 31(11):4412–4418
12. Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661–3679
13. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smauldone MC, Frank I, Gettman MT (2013) Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol 64(1):11–16
14. Hollis RH, Cannon JA, Singletary BA, Korb ML, Hawn MT, Heslin MJ (2016) Understanding the value of both laparoscopic and robotic approaches compared to the open approach in colorectal surgery. J Laparoendosc Adv Surg Tech 26(11):850–856
15. Liao C-H, Tan EC-H, Chen C-C, Yang M-C (2017) Real-world cost-effectiveness of laparoscopic versus open colectomy for colon cancer: a nationwide population-based study. Surg Endosc 31(4):1796–1805
16. Khorgami Z, Li WT, Jackson TN, Howard CA, Sclabas GM (2019) The cost of robotics: an analysis of the added costs of robotic-assisted versus laparoscopic surgery using the National Inpatient Sample. Surg Endosc 33(7):2217–2221
17. Crawshaw BP, Chien H-L, Augustad KM, Delaney CP (2015) Effect of laparoscopic surgery on health care utilization and costs in patients who undergo colectomy. JAMA Surg 150(5):410–415
18. Sheetz KH, Norton EC, Regenbogen SE, Dimick JB (2017) An instrumental variable analysis comparing medicare expenditures for laparoscopic vs open colectomy. JAMA Surg 152(10):921–929
19. Wei D, Johnston S, Goldstein L, Nagle D (2020) Minimally invasive colectomy is associated with reduced risk of anastomotic leak and other major perioperative complications and reduced hospital resource utilization as compared with open surgery: a retrospective population-based study of comparative effectiveness and trends of surgical approach. Surg Endosc 34(2):610–621
20. Jacobs M, Verdeja JC, Goldstein HS (1991) Minimally invasive colon resection (laparoscopic colectomy). Surg Laparosc Endosc 1(3):144–150
21. Group CooSTS (2004) A comparison of laparoscopically assisted and open colecotomy for colon cancer. N Engl J Med 350(20):2050–2059
22. Merola G, Scuotto P, Pirozzi F, Andreuccetti J, Pignata G, Corcione F, Milone M, De Palma GD, Castaldo R, Pecchia L (2020) Is robotic right colectomy economically sustainable? A multicentre retrospective comparative study and cost analysis. Surg Endosc 34(9):4041–4047
23. Park JS, Kang H, Park SY, Kim HJ, Woo IT, Park I-K, Choi G-S (2019) Long-term oncologic after robotic versus laparoscopic right colectomy: a prospective randomized study. Surg Endosc 33(9):2975–2981
24. Hancock KJ, Klimberg VS, Nunez-Lopez O, Gajjar AH, Gomez G, Tyler DS, Rashidi L (2021) Optimizing outcomes in colorectal surgery: cost and clinical analysis of robotic versus laparoscopic approaches to colon resection. J Robotic Surg. https://doi.org/10.1007/s11701-021-01205-8
25. Rashidi L, Neighorn C, Bastawrous A (2017) Outcome comparisons between high-volume robotic and laparoscopic surgeons in a large healthcare system. Am J Surg 213(5):901–905
26. Bastawrous A, Baer C, Rashidi L, Neighorn C (2018) Higher robotic colorectal surgery volume improves outcomes. Am J Surg 215(5):874–878
27. Ferri V, Quijano Y, Nuñez J, Caruso R, Duran H, Diaz E, Fabra I, Malave L, Isernia R, d’Ovidio A (2021) Robotic-assisted right colectomy versus laparoscopic approach: case-matched study and cost-effectiveness analysis. J Robot Surg 15(1):115–123
28. Cleary RK, Kassir A, Johnson CS, Bastawrous AL, Soliman MK, Marx DS, Giordano L, Reedij TJ, Parra-Davila E, Obias VJ (2018) Intracorporeal versus extracorporeal anastomosis for minimally invasive right colectomy: a multi-center propensity score-matched comparison of outcomes. PLoS ONE 13(10):e0206277
29. Cleary RK, Silviera M, Reedij TJ, McCormick J, Johnson CS, Sylla P, Cannon J, Lujan H, Kassir A, Landmann R (2021) Intracorporeal and extracorporeal anastomosis for robotic-assisted and laparoscopic right colectomy: short-term outcomes of a multicenter prospective trial. Surg Endosc. https://doi.org/10.1007/s00464-021-08780-9

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.